1. At a Glance – The Comeback Kid with a GST Headache
₹39 stock price. ₹2,138 crore market cap. Quarterly sales of ₹484 crore. PAT of ₹28 crore. Quarterly EPS ₹0.50. TTM EPS ₹1.82. P/E around 28. ROCE 15.1%. ROE 11.8%. Debt-to-equity just 0.13.
And yet the stock is down 29% in one year and 14% in the last three months.
Welcome to Morepen Laboratories Ltd, a company that dominates Montelukast with 70% market share, rules Loratadine at 69%, and still manages to look like a mid-cap struggler in the stock market.
Q3 FY26 numbers (Dec 2025 quarter) show sales of ₹484 crore — highest in the last four quarters — and PAT of ₹28 crore. OPM back to 10%. But then you see a ₹117.94 crore GST show cause notice (stay granted by High Court), a QIP of ₹200 crore, and a business restructuring where medical devices are being hived off into a subsidiary.
Is this a clean pharma turnaround story?
Or a complicated family-owned pharma saga with a medical device side hustle?
Let’s open the lab coat and see what’s brewing.
2. Introduction – From Penny Stock to Pharma Contender?
Morepen is not a new kid on the Dalal Street block. It has been around for decades, survived the early 2000s pharma debt disasters, and quietly rebuilt itself.
Today it operates across:
- APIs
- Finished formulations
- OTC products under Dr. Morepen
- Medical devices (glucometers, BP monitors, strips)
It claims leadership in 6 APIs globally. Montelukast? 70%. Loratadine? 69%. Desloratadine? 49%.
That’s not small talk. That’s global dominance in anti-allergy and respiratory molecules.
But here’s the twist.
Despite being a volume leader, profitability isn’t blockbuster-level. TTM OPM is 8%. ROE is 11.8%. This isn’t Divi’s Labs territory. This is mid-tier grinder pharma.
And now management says: target ₹5,000 crore revenue by 2030.
Current revenue? ₹1,787 crore (TTM).
So they want to nearly triple in 5 years.
Ambitious? Yes.
Impossible? Not necessarily.
Easy? Absolutely not.
3. Business Model – WTF Do They Even Do?
Let’s simplify this for the lazy but intelligent investor.
1) API Business (75% of Pharma segment)
They manufacture bulk drug ingredients. These are sold to pharma companies globally.
Key molecules:
- Montelukast
- Loratadine
- Desloratadine
- Fexofenadine
- Atorvastatin
- Rosuvastatin
They export to 80+ countries and serve 1,200+ customers.
In H1 FY25, API business grew 9% YoY — driven by exports to Western markets. They are intentionally shifting from low-margin domestic to higher-margin Western markets.
Smart move.
But API business is cyclical. One price erosion cycle and margins evaporate faster than your SIP during a smallcap crash.
2) Finished Formulations & OTC
This includes prescription drugs and OTC products like Burnol and Lemolate under the Dr. Morepen brand.
Brand building = better margins.
But building brands = heavy marketing spend.
3) Medical Devices (30% revenue in H1 FY25)
Glucometers, strips, BP monitors.
They’ve sold:
- 1,750 million+ Gluco strips
- 6.33 million BP monitors
Medical devices business grew 9.35% YoY in H1 FY25.
Now here’s the twist:
They are transferring this business to a subsidiary — Morepen Medtech Ltd.
Why?
Value unlocking?
Regulatory separation?
Or accounting neatness?
Interesting move.
